These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23663372)

  • 1. [Limited effect of interferon-beta for the treatment of secondary progressive multiple sclerosis].
    Schreiber K; Voldsgaard A; Sørensen PS
    Ugeskr Laeger; 2013 May; 175(19):1342-4. PubMed ID: 23663372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta for secondary progressive multiple sclerosis.
    La Mantia L; Vacchi L; Di Pietrantonj C; Ebers G; Rovaris M; Fredrikson S; Filippini G
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005181. PubMed ID: 22258960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon β for secondary progressive multiple sclerosis: a systematic review.
    La Mantia L; Vacchi L; Rovaris M; Di Pietrantonj C; Ebers G; Fredrikson S; Filippini G
    J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):420-6. PubMed ID: 22952326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis.
    Angelucci F; Mirabella M; Caggiula M; Frisullo G; Patanella K; Sancricca C; Nociti V; Tonali PA; Batocchi AP
    Peptides; 2005 Nov; 26(11):2289-93. PubMed ID: 16269354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
    Panitch H; Miller A; Paty D; Weinshenker B;
    Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
    Andersen O; Elovaara I; Färkkilä M; Hansen HJ; Mellgren SI; Myhr KM; Sandberg-Wollheim M; Soelberg Sørensen P
    J Neurol Neurosurg Psychiatry; 2004 May; 75(5):706-10. PubMed ID: 15090564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
    Kappos L; Weinshenker B; Pozzilli C; Thompson AJ; Dahlke F; Beckmann K; Polman C; McFarland H; ;
    Neurology; 2004 Nov; 63(10):1779-87. PubMed ID: 15557490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
    Kobelt G; Jönsson L; Miltenburger C; Jönsson B
    Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Secondary progressive multiple sclerosis in childhood--interferon beta 1b treatment].
    Higurashi N; Hamano S; Eto Y
    No To Hattatsu; 2006 May; 38(3):209-13. PubMed ID: 16715936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
    Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L;
    Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunologic therapy for secondary and primary progressive multiple sclerosis].
    Ozawa K
    Nihon Rinsho; 2003 Aug; 61(8):1449-54. PubMed ID: 12962037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
    Tur C; Montalban X; Tintoré M; Nos C; Río J; Aymerich FX; Brieva L; Téllez N; Perkal H; Comabella M; Galán I; Calle D; Sastre-Garriga J; Rovira A
    Arch Neurol; 2011 Nov; 68(11):1421-7. PubMed ID: 22084124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A meta-analysis of interferon-beta in the secondary progressive multiple sclerosis].
    Fan X; Yang L
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(21):1484-9. PubMed ID: 19953902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta 1a for secondary progressive multiple sclerosis.
    Hughes RA
    J Neurol Sci; 2003 Feb; 206(2):199-202. PubMed ID: 12559511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status of interferon beta-1b in multiple sclerosis therapy].
    Hartung HP
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of drugs in secondary disease progression in patients with multiple sclerosis.
    Kappos L
    Mult Scler; 2004 Jun; 10 Suppl 1():S46-54; discussion S54-5. PubMed ID: 15218809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.